{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T11:03:03Z","timestamp":1779793383879,"version":"3.53.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzen Municipality","doi-asserted-by":"publisher","award":["SZSM202301035"],"award-info":[{"award-number":["SZSM202301035"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002857","name":"China Pharmaceutical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173887"],"award-info":[{"award-number":["82173887"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dmd.2026.100263","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:26:07Z","timestamp":1772483167000},"page":"100263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A minimal physiologically based pharmacokinetic model for predicting the metabolism of tenofovir prodrugs in the liver of human with fibrosis"],"prefix":"10.1016","volume":"54","author":[{"given":"Hua","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4386-0110","authenticated-orcid":false,"given":"Jingwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2026.100263_bib1","series-title":"Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact","year":"2021"},{"issue":"10127","key":"10.1016\/j.dmd.2026.100263_bib2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/cld.162","article-title":"Hepatitis B virus treatment: management of antiviral drug resistance","volume":"2","author":"Tana","year":"2013","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"17","key":"10.1016\/j.dmd.2026.100263_bib4","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jama.2018.3795","article-title":"Chronic hepatitis B infection: A review","volume":"319","author":"Tang","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4254\/wjh.v9.i1.48","article-title":"Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience","volume":"9","author":"Lovett","year":"2017","journal-title":"World J Hepatol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100263_bib6","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"issue":"suppl 8","key":"10.1016\/j.dmd.2026.100263_bib7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12859-016-1116-4","article-title":"Modeling the functional state of the reverse transcriptase of hepatitis B virus and its application to probing drug-protein interaction","volume":"17","author":"Xu","year":"2016","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.dmd.2026.100263_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2020.113611","article-title":"An LC-MS\/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer","volume":"593","author":"Xiao","year":"2020","journal-title":"Anal Biochem"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib9","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.dmd.2026.100263_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/psp4.12583","article-title":"A mechanistic in vivo\/ex vivo pharmacokinetic-pharmacodynamic model of tenofovir for HIV prevention","volume":"10","author":"Jayachandran","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100263_bib11","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/jps.24468","article-title":"A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design","volume":"104","author":"Poulin","year":"2015","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100263_bib12","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cbpa.2009.04.620","article-title":"Prodrugs: bridging pharmacodynamic\/pharmacokinetic gaps","volume":"13","author":"Testa","year":"2009","journal-title":"Curr Opin Chem Biol"},{"issue":"13","key":"10.1016\/j.dmd.2026.100263_bib13","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1128\/JVI.00311-11","article-title":"Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors","volume":"85","author":"Garcia-Lerma","year":"2011","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/mp3002045","article-title":"Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340","volume":"10","author":"Babusis","year":"2013","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/hep.28916","article-title":"Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment","volume":"66","author":"Kim","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.dmd.2026.100263_bib16","article-title":"Risk factors related to low-level viraemia in chronic hepatitis B patients receiving entecavir treatment","volume":"14","author":"Li","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"11","key":"10.1016\/j.dmd.2026.100263_bib17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/00003088-200645110-00005","article-title":"Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment","volume":"45","author":"Kearney","year":"2006","journal-title":"Clin Pharmacokineti"},{"key":"10.1016\/j.dmd.2026.100263_bib18","series-title":"Vemlidy (tenofovir alafenamide) [package insert]","year":"2021"},{"key":"10.1016\/j.dmd.2026.100263_bib19","series-title":"Viread (tenofovir disoproxil fumarate) [package insert]","year":"2019"},{"issue":"13","key":"10.1016\/j.dmd.2026.100263_bib20","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.3748\/wjg.v23.i13.2396","article-title":"Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis","volume":"23","author":"Lee","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jconrel.2013.04.025","article-title":"Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion","volume":"172","author":"Stern","year":"2013","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yrtph.2015.06.019","article-title":"Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats","volume":"73","author":"Sweeney","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.dmd.2026.100263_bib23","first-page":"3365","article-title":"A physiologically based pharmacokinetic model for ionic silver and silver nanoparticles","volume":"8","author":"Bachler","year":"2013","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.dmd.2026.100263_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.taap.2017.08.018","article-title":"A two-step model of TiO2 nanoparticle toxicity in human liver tissue","volume":"334","author":"Laomettachit","year":"2017","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.dmd.2026.100263_bib25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-pharmtox-010510-100540","article-title":"Physiologically-based pharmacokinetics in drug development and regulatory science","volume":"51","author":"Rowland","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1124\/dmd.116.072652","article-title":"Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC-MS\/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants","volume":"45","author":"Boberg","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/toxsci\/kfz211","article-title":"Development and application of a life-stage physiologically based pharmacokinetic (PBPK) model to the assessment of internal dose of pyrethroids in humans","volume":"173","author":"Mallick","year":"2020","journal-title":"Toxicol Sci"},{"issue":"9","key":"10.1016\/j.dmd.2026.100263_bib28","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40262-014-0160-3","article-title":"Physiologically based pharmacokinetic modeling of impaired carboxylesterase-1 activity: effects on oseltamivir disposition","volume":"53","author":"Hu","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100263_bib29","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.xphs.2016.12.001","article-title":"In vitro-in vivo extrapolation of intestinal availability for carboxylesterase substrates using portal vein-cannulated monkey","volume":"106","author":"Trapa","year":"2017","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100263_bib30","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/0091270010396373","article-title":"Population pharmacokinetic model for a novel oral hypoglycemic formed in vivo: comparing the use of active metabolite data alone versus using data of upstream and downstream metabolites","volume":"52","author":"Kastrissios","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2026.100263_bib31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.phymed.2018.09.010","article-title":"Systematically identifying the hepatoprotective ingredients of schisandra lignan extract from pharmacokinetic and pharmacodynamic perspectives","volume":"53","author":"Kang","year":"2019","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3797","article-title":"Bioanalytical assay development and validation for simultaneous quantification of five schisandra lignans in rat primary hepatocytes based on LC-MS\/MS: application to a real-time uptake study for Schisandra Lignan Extract","volume":"31","author":"Kang","year":"2017","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.dmd.2026.100263_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jpba.2017.08.028","article-title":"Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected. hepatocyte with a sensitive LC-MS\/MS method","volume":"146","author":"Ouyang","year":"2017","journal-title":"J Pharmaceut Biomed"},{"key":"10.1016\/j.dmd.2026.100263_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.932934","article-title":"Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models","volume":"13","author":"Hong","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib35","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2284286","article-title":"Engineered extracellular vesicles for delivering functional Cas9\/gRNA to eliminate hepatitis B virus cccDNA and integration","volume":"13","author":"Zeng","year":"2024","journal-title":"Emerg Microbes Infect"},{"issue":"6","key":"10.1016\/j.dmd.2026.100263_bib36","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.00128-15","article-title":"Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy","volume":"59","author":"Murakami","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmd.2026.100263_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jchromb.2019.04.011","article-title":"Simultaneous determination of tenofovir alafenamide and tenofovir in human plasma by LC-MS\/MS and its application to pharmacokinetics study in clinic","volume":"1117","author":"Zhao","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"9","key":"10.1016\/j.dmd.2026.100263_bib38","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1128\/AAC.00005-16","article-title":"Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment","volume":"60","author":"Custodio","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.dmd.2026.100263_bib39","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","article-title":"Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals","volume":"78","author":"Begley","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"10.1016\/j.dmd.2026.100263_bib40","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0091270007300951","article-title":"Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers","volume":"47","author":"Blum","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100263_bib41","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1093\/jac\/dkz187","article-title":"Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate","volume":"74","author":"Brooks","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib42","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40121-021-00555-y","article-title":"Study on pharmacokinetic interactions between HS-10234 and emtricitabine in healthy subjects: an open-label, two-sequence, self-controlled phase I trial","volume":"11","author":"Luo","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.16196","article-title":"Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection","volume":"53","author":"Zhang","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100263_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/cpt.37","article-title":"Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective","volume":"97","author":"Jones","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmd.2026.100263_bib45","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1124\/dmd.117.076851","article-title":"Physiologically based pharmacokinetic model predictions of panobinostat (LBH589) as a victim and perpetrator of drug-drug interactions","volume":"45","author":"Einolf","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100263_bib46","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/jac\/dky192","article-title":"Model of population pharmacokinetics of cidofovir in immunocompromised children with cytomegalovirus and adenovirus infection","volume":"73","author":"Neant","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.dmd.2026.100263_bib47","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s40262-022-01175-6","article-title":"Quantification of the time course of CYP3A inhibition, activation, and induction using a population pharmacokinetic model of microdosed midazolam continuous infusion","volume":"61","author":"Nassar","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.dmd.2026.100263_bib48","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"10.1016\/j.dmd.2026.100263_bib49","doi-asserted-by":"crossref","DOI":"10.1088\/1742-6596\/2747\/1\/012025","article-title":"An improved Sobol sensitivity analysis method","volume":"2747","author":"Chen","year":"2024","journal-title":"J Phys Conf Ser"},{"issue":"5","key":"10.1016\/j.dmd.2026.100263_bib50","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bcp.12685","article-title":"Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women","volume":"80","author":"De Sousa Mendes","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib51","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41598-024-51430-y","article-title":"A new investigation on fractionalized modeling of human liver","volume":"14","author":"Bhatter","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12234","article-title":"Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data","volume":"79","author":"Tsamandouras","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"10.1016\/j.dmd.2026.100263_bib53","first-page":"4611","article-title":"Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model","volume":"55","author":"Baxter","year":"1995","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.dmd.2026.100263_bib54","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s11095-015-1703-5","article-title":"Across-species scaling of monoclonal antibody pharmacokinetics using a minimal PBPK model","volume":"32","author":"Zhao","year":"2015","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.dmd.2026.100263_bib55","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","article-title":"Applications of minimal physiologically-based pharmacokinetic models","volume":"39","author":"Cao","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"10.1016\/j.dmd.2026.100263_bib56","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/00498254.2018.1547461","article-title":"Application of unbound liver-to-plasma concentration ratio to quantitative projection of cytochrome P450-mediated drug-drug interactions using physiologically based pharmacokinetic modelling approach","volume":"49","author":"Iwasaki","year":"2019","journal-title":"Xenobiotica"},{"issue":"suppl 1","key":"10.1016\/j.dmd.2026.100263_bib57","first-page":"S108","article-title":"Spreadsheet-based minimal physiological models for the prediction of clearance of therapeutic proteins in pediatric patients","volume":"61","author":"Mahmood","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100263_bib58","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10928-021-09776-7","article-title":"Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases","volume":"48","author":"Bloomingdale","year":"2021","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.dmd.2026.100263_bib59","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuro.2016.12.001","article-title":"The application of PBPK models in estimating human brain tissue manganese concentrations","volume":"58","author":"Ramoju","year":"2017","journal-title":"Neurotoxicology"},{"issue":"3","key":"10.1016\/j.dmd.2026.100263_bib60","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/molecules25030535","article-title":"Pharmacokinetic characterization and tissue distribution of fusion protein therapeutics by orthogonal bioanalytical assays and minimal PBPK modeling","volume":"25","author":"Sugimoto","year":"2020","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.dmd.2026.100263_bib61","doi-asserted-by":"crossref","first-page":"e00105","DOI":"10.1128\/AAC.00105-17","article-title":"Simulating intestinal transporter and enzyme activity in a physiologically based pharmacokinetic model for tenofovir disoproxil fumarate","volume":"61","author":"Moss","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.dmd.2026.100263_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00155-20","article-title":"Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using physiologically based pharmacokinetic modelling","volume":"64","author":"Rajoli","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.dmd.2026.100263_bib63","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.lfs.2007.07.026","article-title":"Carboxylesterase in the liver and small intestine of experimental animals and human","volume":"81","author":"Taketani","year":"2007","journal-title":"Life Sci"},{"issue":"9","key":"10.1016\/j.dmd.2026.100263_bib64","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1517\/17425255.2014.934671","article-title":"The application of allometric scaling principles to predict pharmacokinetic parameters across species","volume":"10","author":"Huang","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib65","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/03602532.2025.2462527","article-title":"Scaling factors to inform in vitro-in vivo extrapolation from preclinical and livestock animals: state of the field and recommendations for development of missing data","volume":"57","author":"Zimmer","year":"2025","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.dmd.2026.100263_bib66","first-page":"1261","article-title":"Interspecies extrapolation by physiologically based pharmacokinetic modeling","volume":"14","author":"Ghallab","year":"2015","journal-title":"EXCLI J"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/mnfr.200400076","article-title":"Interspecies metabolism of heterocyclic aromatic amines and the uncertainties in extrapolation of animal toxicity data for human risk assessment","volume":"49","author":"Turesky","year":"2005","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.dmd.2026.100263_bib68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res"},{"issue":"9","key":"10.1016\/j.dmd.2026.100263_bib69","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s11095-023-03581-2","article-title":"Effect of P-glycoprotein and cotreatment with sofosbuvir on the intestinal permeation of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate","volume":"40","author":"Huliciak","year":"2023","journal-title":"Pharm Res"},{"issue":"12","key":"10.1016\/j.dmd.2026.100263_bib70","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1016\/j.xphs.2023.09.009","article-title":"Plasma protein binding determination for unstable ester prodrugs: remdesivir and tenofovir alafenamide","volume":"112","author":"Wen","year":"2023","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.dmd.2026.100263_bib71","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2165\/00003088-200847110-00005","article-title":"Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis","volume":"47","author":"Edginton","year":"2008","journal-title":"Clin Pharmacokinet"},{"issue":"64","key":"10.1016\/j.dmd.2026.100263_bib72","doi-asserted-by":"crossref","first-page":"S594","DOI":"10.1016\/S0168-8278(16)01095-3","article-title":"Pharmacokinetics and safety of tenofovir alafenamide in subjects with severe hepatic impairment","volume":"2","author":"Custodie","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100263_bib73","first-page":"687","article-title":"Emerging evidence of inter-organ interaction on drug transporters under liver injury","volume":"23","author":"Jiang","year":"2025","journal-title":"Chin J Nat Med"},{"issue":"1","key":"10.1016\/j.dmd.2026.100263_bib74","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13550-024-01105-6","article-title":"Biodistribution and radiation dosimetry of [99mTc] Tc-N4-BTG in patients with biochemical recurrence of prostate cancer","volume":"14","author":"Rinscheid","year":"2024","journal-title":"EJNMMI Res"},{"issue":"6","key":"10.1016\/j.dmd.2026.100263_bib75","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.124.269132","article-title":"First-in-human serum stability studies of [177Lu] Lu-AMTG: a step toward improved GRPR-targeted radiopharmaceutical therapy","volume":"66","author":"Felber","year":"2025","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1016\/j.dmd.2026.100263_bib76","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1124\/jpet.121.000805","article-title":"Minimal physiologically based pharmacokinetic-pharmacodynamic (mPBPK-PD) model of N-acetylgalactosamine\u2013conjugated small interfering RNA disposition and gene silencing in preclinical species and humans","volume":"379","author":"Ayyar","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100263_bib77","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40262-025-01513-4","article-title":"Prediction of interspecies translation for targeting delivery coefficients of GalNAc-siRNA silencing apolipoprotein C-III using a mechanistic minimal physiologically based pharmacokinetic\/pharmacodynamic model","volume":"64","author":"Tian","year":"2025","journal-title":"Clin Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T10:13:25Z","timestamp":1779790405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0090955626000322"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100263","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A minimal physiologically based pharmacokinetic model for predicting the metabolism of tenofovir prodrugs in the liver of human with fibrosis","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100263"}}